



Steve Kirsch's ne...

Subscribe

Sign in

How the FDA justified rejecting an EUA for fluvoxamine

The drug works great. But the FDA doesn't want anyone to know that. Why? Because they are corrupt. They will never agree to debate me on that.



Steve Kirsch

20 hr ago

511

293



Summary

Fluvoxamine has a systematic review and meta-analysis published in a top medical journal.

© 2022 Steve Kirsch · [Privacy](#) · [Terms](#) · [Collection notice](#)

 Publish on Substack

 Get the app

[Substack](#) is the home for great writing

The FDA approved Molnupiravir which was less effective. Why not fluvoxamine?

ICER, a non-profit known as the nation's drug pricing watchdog, did a review of the evidence and determined that fluvoxamine evidence is superior to Molnupiravir.

It can't be more clear than this. The reason is pure corruption.

But I know something else that few other people know, thanks to a source at the NIH: the NIH was planning to approve fluvoxamine months ago, but they got a call from the FDA telling them not to.

This is how science works today.

This post was written to memorialize the corruption.

Background documents

1. [Original Boulware EUA application](#)
2. [JAMA systematic review and meta analysis](#) It doesn't get any better than this. This is the "gold standard of evidence based medicine"
3. [FDA official fluvoxamine rejection](#)
4. [Article about the rejection](#) (Stat News)
5. [Article about the fluvoxamine rejection](#) (The Verge)
6. [NIH is still unsure whether fluvoxamine should be used to treat COVID](#) (article I did after the TOGETHER trial). The NIH wrote a bullshit rejection because the FDA told them not to approve it.
7. The ICER independent review showed fluvoxamine is more effective than Molnupiravir:



Angela Reiersen, MD, MPE

@AngelaReiersen

ICER:

"... committee votes 11-2 that the evidence is not adequate to demonstrate a net health benefit for molnupiravir over symptomatic care alone; Paxlovid and fluvoxamine receive more favorable votes"





ICER Publishes Final Evidence Report and Policy Recommendations on Outpatient Treatments for COVID-19 - ICER

Independent appraisal committee votes 11-2 that the evidence is not adequate to demonstrate a net health benefit for molnupiravir over symptomatic care alone; Paxlovid and fluvoxamine receive more favorable votes.

icer.org

May 16th 2022

6 Retweets 30 Likes

Using fluvoxamine

Read this article I wrote about [using fluvoxamine correctly for COVID](#). It is an amazing drug and is a very simple safe way to avoid long-haul COVID symptoms.

Taking apart the FDA's argument

These people never called the researchers whose trials they claimed showed no effect.

The trials that were abandoned for futility weren't getting events because the patients were given standard of care meds. So there were too few events in the placebo group and they weren't recruiting fast enough. So the drug had no chance of working (since there were no events), so the trial was stopped for futility, NOT because the drug doesn't work. All the researchers are convinced the drug works.

Fluvoxamine has at least a 30% hospitalization and death benefit.

Expect similar things to happen when Eiger applies for an EUA for interferon lambda, a drug with a 89% efficacy in phase 3 trials.

It's not about the science. It never was.

Subscribe to Steve Kirsch's newsletter

Thousands of paid subscribers

I write about COVID vaccine safety and efficacy, corruption, censorship, mandates, masking, and early treatments. America is being misled by formerly trusted authorities.

♥ 511

💬 293

🔗 Share



Write a comment...



Steve Kirsch 16 hr ago 📌 Pinned

I fixed the link to the fluvoxamine article. sorry about that. I wanted to get the article out before my flight left.

♥ 22 Reply

13 replies



Brandy 1 hr ago

Pharmaceutical companies need a new stream of revenue (enter mRNA injections) since most conventional drugs are now off patent and children already have 70 doses of required vaccines. They can't keep reinventing the same drugs over and over for the same chronic diseases indefinitely, although they are doing a pretty decent job so far. But the end of that business model is near. They are now working quite successfully with government, big tech and corporate media to require/mandate frequent adult vaccines moving forward. How many billions did they make this past year? With no research investment of their own and complete liability protection? It's brilliant, if hoards of money is the only goal. It's evil, if the well being of society is the ultimate

goal. Brandy Vaughn warned that this was what big pharma was after just before her untimely, mysterious death.

 Reply Give gift

291 more comments...

Ready for more?

Type your email...

Subscribe